Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics, Inc. (GLUE) Principal Accounting Officer Matthew Bowen sold 13 shares of common stock on October 5, 2026, at $10.56 per share. The shares were required to be sold to cover tax withholding obligations tied to restricted stock unit vesting; the sales were automatic and not at his discretion. He directly held 25,891 shares after the transaction.
Monte Rosa Therapeutics, Inc. (GLUE) reported Phase 1 GFORCE-1 results for MRT-8102, a NEK7-directed molecular glue degrader being developed for NLRP3/IL-1-driven inflammatory diseases. The study enrolled 108 obese participants with elevated cardiovascular risk, who received once-daily doses of 5 mg, 20 mg or 40 mg, or placebo, followed by four weeks of safety follow-up after four weeks of dosing.
MRT-8102 produced median NEK7 degradation of approximately 80% to 90% across doses. After four weeks, median reductions included 56% for calprotectin, 46% for S100A12, 51% for SAA, 28% for fibrinogen, 54% for IL-6, 85% for hsCRP and 24% for lipoprotein(a). Treatment-emergent adverse events occurred in 33% of MRT-8102 participants and 30% of placebo participants; no serious adverse events were reported. Adverse events led to treatment discontinuation in 11% of the 20 mg group and 19% of the 40 mg group.
Monte Rosa expects GFORCE-2 in stable coronary artery disease to begin in H1 2027, with its six-month design pending regulatory feedback. GEMINI-1 in gout is expected in Q4 2026 or Q1 2027, and GALAXY-1 in hidradenitis suppurativa in H1 2027.
Monte Rosa Therapeutics, Inc. (GLUE) announced that collaborator Novartis has initiated a Phase 2 clinical study of the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in people with Sjögren’s disease, triggering a $50 million milestone payment to Monte Rosa under their global license agreement.
Novartis holds exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1-directed molecular glue degraders and is responsible for funding and conducting Phase 2 studies, while Monte Rosa will co-fund any Phase 3 development and share 30% of U.S. profits and losses. Monte Rosa is additionally eligible to receive up to $2.1 billion in development, regulatory and sales milestones, as well as tiered royalties on ex-U.S. net sales.
The Phase 2a/b trial is randomized, double-blind, placebo-controlled and multi-center, evaluating efficacy, safety and tolerability over up to 52 weeks of treatment to support Phase 3 dose selection. Prior Phase 1 data for MRT-6160 showed sustained, dose-dependent VAV1 degradation of greater than 90% in peripheral blood T cells and was generally well tolerated.
Monte Rosa Therapeutics, Inc. is the subject of an amended Schedule 13G filing by Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen regarding holdings of its common stock (CUSIP 61225M102). The reporting persons collectively report beneficial ownership below five percent of the outstanding common stock.
Certain reporting persons beneficially own 3,549,539 shares, representing 4.2% of the class, and Averill Master Fund, Ltd. beneficially owns 3,215,486 shares, or 3.8% of the class. For each reporting person, there is no sole voting or dispositive power; all voting and dispositive authority over these shares is described as shared. The reporting persons state that they disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.
Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of Monte Rosa Therapeutics, Inc. common stock on a passive basis. They collectively report beneficial ownership of 4,600,000 shares of Common Stock, representing 5.4% of the outstanding shares.
Their ownership is held through a fund and a managed account advised by Vestal Point Capital, LP, with shared voting and dispositive power over 4,600,000 shares and no sole voting or dispositive power. The percentage ownership is based on 84,479,418 shares outstanding as of May 1, 2026. The Vestal Point fund and account have the right to receive dividends and sale proceeds for these shares.
Monte Rosa Therapeutics, a clinical-stage biotech focused on molecular glue degraders, reported sharply lower collaboration revenue and wider losses for the quarter and six months ended June 30, 2026. Collaboration revenue was $8,968 (in thousands) in the quarter and $13,178 (in thousands) year‑to‑date, down from $23,194 and $108,123 (in thousands) a year earlier, mainly because the large 2024 Novartis upfront payment was fully recognized in 2025.
Research and development spending rose to $47,964 (in thousands) for the quarter and $92,033 (in thousands) year‑to‑date, reflecting pipeline advancement and discovery work; total operating expenses reached $58,098 and $112,342 (in thousands). Net loss was $43,397 (in thousands), or $0.43 per share, for the quarter and $87,900 (in thousands), or $0.87 per share, for the first half of 2026, compared with net income of $34,590 (in thousands) in the prior‑year period.
Cash, cash equivalents and marketable securities totaled $621.1 million as of June 30, 2026, or $626.0 million including restricted cash, and the company states this supports its cash runway into 2029. Deferred revenue of $15.2 million from Roche and $112.5 million from the 2025 Novartis Agreement provides future collaboration revenue as Monte Rosa advances programs such as MRT‑2359, MRT‑8102 and VAV1‑directed MRT‑6160.
Monte Rosa Therapeutics reported second-quarter 2026 collaboration revenue of $9.0 million, down from $23.2 million a year earlier, as R&D spending rose to $48.0 million and G&A to $10.1 million. The quarter’s net loss widened to $43.4 million from $12.3 million.
Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0 million as of June 30, 2026, which the company expects will fund operations into 2029. Clinically, enrollment and dosing in the GFORCE-1 Phase 1 study of MRT-8102 in elevated cardiovascular risk are complete, with data expected in the second half of 2026 and multiple Phase 2 trials planned in cardiometabolic risk, gout, and hidradenitis suppurativa.
Novartis has activated a Phase 2 study of MRT-6160 in Sjögren’s disease under a collaboration that could provide up to $2.1 billion in milestones, while Monte Rosa activated the MODeFIRe-1 Phase 2 study of MRT-2359 in metastatic castration-resistant prostate cancer and continues advancing cyclin E1 and CDK2-directed molecular glue degrader programs toward an expected IND filing in 2027.
Monte Rosa Therapeutics, Inc. President & CEO Markus Warmuth reported an open-market sale of 9,500 shares of Common Stock on July 16, 2026. The shares were sold at a weighted average price of $23.1809 per share, with individual trades between $23.18 and $23.23. Following this transaction, Warmuth directly holds 585,038 shares of Monte Rosa Therapeutics. The transaction is not indicated as made under a Rule 10b5-1 trading plan.
Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported option-related trades in common stock. She exercised stock options to acquire 4,351 shares at $3.98 per share and, on the same date, sold 4,351 shares at a weighted average price of $23.3808 under a Rule 10b5-1 trading plan adopted on February 19, 2026.
After these transactions, she directly holds 62,371 common shares and 26,947 stock options (right to buy) expiring on June 3, 2034. The sale transactions occurred in a price range of $22.83 to $23.71 per share.
GLUE shareholder Markus Warmuth filed a notice to sell up to 9,500 shares of GLUE common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $220,218.55. The approximate sale date is July 16, 2026 on NASDAQ.
The 9,500 shares derive from restricted stock acquired from the issuer, including 8,678 shares granted on September 1, 2021 and 822 shares on December 1, 2021. In the past three months, Warmuth sold 5,466 shares for $106,253.04 on June 1, 2026 and 5,467 shares for $103,446.57 on May 1, 2026. Shares outstanding were 84,479,418.